{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:50:44Z","timestamp":1786632644730,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"JSS Academy of Higher Education and Research, Mysore"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-60339-7","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:10:20Z","timestamp":1786630220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Anisha","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Dharmashekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargav","family":"Shreevatsa K S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amogha","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva Prasad","family":"Kollur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Shivamallu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. N. Nagendra","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"60339_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"60339_CR2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","volume":"156","author":"K Sathishkumar","year":"2022","unstructured":"Sathishkumar, K. et al. Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian J. Med. Res. 156, 598\u2013607 (2022).","journal-title":"Indian J. Med. Res."},{"issue":"2","key":"60339_CR3","first-page":"189","volume":"1856","author":"H Lemjabbar-Alaoui","year":"2015","unstructured":"Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y. W. & Buchanan, P. Lung cancer: Biology and treatment options. Biochim. Biophys. Acta. 1856(2), 189\u2013210 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"60339_CR4","doi-asserted-by":"publisher","first-page":"741326","DOI":"10.3389\/fonc.2021.741326","volume":"11","author":"AS Jain","year":"2021","unstructured":"Jain, A. S. et al. Everything old is new again: drug repurposing approach for non-small cell lung cancer targeting MAPK signaling pathway. Front. Oncol. 11, 741326 (2021).","journal-title":"Front. Oncol."},{"key":"60339_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446\u2013454 (2018).","journal-title":"Nature"},{"key":"60339_CR6","doi-asserted-by":"crossref","unstructured":"Duma, N., Santana-Davila, R. & Molina, J. R. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc. 94, 1623\u20131640 (2019).","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"60339_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4155\/fmc-2018-0468","volume":"11","author":"R Pradhan","year":"2019","unstructured":"Pradhan, R., Singhvi, G., Dubey, S. K., Gupta, G. & Dua, K. MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma. Future Med. Chem. 11, 793\u2013795 (2019).","journal-title":"Future Med. Chem."},{"key":"60339_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2018.07.013","volume":"124","author":"I Ferrer","year":"2018","unstructured":"Ferrer, I. et al. KRAS-mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 124, 53\u201364 (2018).","journal-title":"Lung Cancer"},{"key":"60339_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu, C. et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol. Cancer. 21, 159 (2022).","journal-title":"Mol. Cancer"},{"key":"60339_CR10","doi-asserted-by":"publisher","first-page":"104228","DOI":"10.1016\/j.critrevonc.2023.104228","volume":"195","author":"R Rosell","year":"2024","unstructured":"Rosell, R. et al. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC). Crit. Rev. Oncol. Hematol. 195, 104228 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"60339_CR11","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","volume":"20","author":"RJ Nichols","year":"2018","unstructured":"Nichols, R. J. et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell. Biol. 20, 1064\u20131073 (2018).","journal-title":"Nat. Cell. Biol."},{"key":"60339_CR12","first-page":"1997","volume":"19","author":"YJ Guo","year":"2020","unstructured":"Guo, Y. J. et al. ERK\/MAPK signalling pathway and tumorigenesis. Exp. Ther. Med. 19, 1997\u20132007 (2020).","journal-title":"Exp. Ther. Med."},{"key":"60339_CR13","doi-asserted-by":"publisher","first-page":"114239","DOI":"10.1016\/j.ejmech.2022.114239","volume":"234","author":"Y Hua","year":"2022","unstructured":"Hua, Y. et al. Drug repositioning: progress and challenges in drug discovery for various diseases. Eur. J. Med. Chem. 234, 114239 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"60339_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/curroncol30010055","volume":"30","author":"G Doumat","year":"2023","unstructured":"Doumat, G. et al. Drug repurposing in non-small cell lung carcinoma: old solutions for new problems. Curr. Oncol. 30, 704\u2013719 (2023).","journal-title":"Curr. Oncol."},{"key":"60339_CR15","doi-asserted-by":"publisher","first-page":"15961","DOI":"10.3390\/ijms232415961","volume":"23","author":"H Zhu","year":"2022","unstructured":"Zhu, H. et al. A comprehensive survey of prospective structure-based virtual screening for early drug discovery in the past fifteen years. Int. J. Mol. Sci. 23, 15961 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"60339_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/pharmaceutics14010059","volume":"14","author":"MK Thirunavukkarasu","year":"2021","unstructured":"Thirunavukkarasu, M. K. et al. In silico screening of available drugs targeting non-small cell lung cancer targets: a drug repurposing approach. Pharmaceutics 14, 59 (2021).","journal-title":"Pharmaceutics"},{"key":"60339_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."},{"key":"60339_CR18","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.sjbs.2020.11.049","volume":"28","author":"AS Jain","year":"2021","unstructured":"Jain, A. S. et al. In silico evaluation of flavonoids as effective antiviral agents on the spike glycoprotein of SARS-CoV-2. Saudi J. Biol. Sci. 28, 1040\u20131051 (2021).","journal-title":"Saudi J. Biol. Sci."},{"key":"60339_CR19","doi-asserted-by":"publisher","first-page":"e0291256","DOI":"10.1371\/journal.pone.0291256","volume":"18","author":"FA Yousif","year":"2023","unstructured":"Yousif, F. A. et al. Repurposing of approved drugs for targeting CDK4\/6 and aromatase protein using molecular docking and molecular dynamics studies. PLoS ONE. 18, e0291256 (2023).","journal-title":"PLoS ONE"},{"key":"60339_CR20","doi-asserted-by":"publisher","first-page":"7947","DOI":"10.1038\/s41598-023-35122-7","volume":"13","author":"K Baby","year":"2023","unstructured":"Baby, K. et al. Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer. Sci. Rep. 13, 7947 (2023).","journal-title":"Sci. Rep."},{"key":"60339_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1042\/BJ20121513","volume":"448","author":"JH Park","year":"2012","unstructured":"Park, J. H., Liu, Y., Lemmon, M. A. & Radhakrishnan, R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem. J. 448, 417\u2013423 (2012).","journal-title":"Biochem. J."},{"key":"60339_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"60339_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596\u2013599 (2010).","journal-title":"Nature"},{"key":"60339_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1021\/ml300049d","volume":"3","author":"KD Rice","year":"2012","unstructured":"Rice, K. D. et al. Novel carboxamide-based allosteric MEK inhibitors: discovery and optimization efforts toward XL518 (GDC-0973). ACS Med. Chem. Lett. 3, 416\u2013421 (2012).","journal-title":"ACS Med. Chem. Lett."},{"key":"60339_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nchembio.1629","volume":"10","author":"A Chaikuad","year":"2014","unstructured":"Chaikuad, A. et al. A unique inhibitor binding site in ERK1\/2 is associated with slow binding kinetics. Nat. Chem. Biol. 10, 853\u2013860 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"60339_CR26","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-20-1634","volume":"80","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib. Cancer Res. 80, 4840\u20134853 (2020).","journal-title":"Cancer Res."},{"key":"60339_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ccell.2020.01.001","volume":"37","author":"J Jiang","year":"2020","unstructured":"Jiang, J. et al. Direct phosphorylation and stabilization of MYC by Aurora B kinase promote T-cell leukemogenesis. Cancer Cell. 37, 200\u2013215 (2020).","journal-title":"Cancer Cell."},{"key":"60339_CR28","doi-asserted-by":"publisher","first-page":"101032","DOI":"10.1016\/j.imu.2022.101032","volume":"32","author":"AT Ogunlana","year":"2022","unstructured":"Ogunlana, A. T. et al. Computer-aided drug design of some KRAS G12C inhibitors: targeting the covalent and allosteric binding site for cancer therapy. Inf. Med. Unlocked. 32, 101032 (2022).","journal-title":"Inf. Med. Unlocked"},{"key":"60339_CR29","doi-asserted-by":"publisher","first-page":"e0268269","DOI":"10.1371\/journal.pone.0268269","volume":"17","author":"AJ Owoloye","year":"2022","unstructured":"Owoloye, A. J. et al. Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors. PLoS ONE. 17, e0268269 (2022).","journal-title":"PLoS ONE"},{"key":"60339_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41419-017-0065-9","volume":"9","author":"ELH Leung","year":"2018","unstructured":"Leung, E. L. H. et al. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Cell. Death Dis. 9, 216 (2018).","journal-title":"Cell. Death Dis."},{"key":"60339_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3389\/fphar.2018.00958","volume":"9","author":"H Lai","year":"2018","unstructured":"Lai, H. et al. Krukovine suppresses KRAS-mutated lung cancer cell growth and proliferation by inhibiting the RAF-ERK pathway and inactivating AKT pathway. Front. Pharmacol. 9, 958 (2018).","journal-title":"Front. Pharmacol."},{"key":"60339_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/diseases6040085","volume":"6","author":"J Gordon","year":"2018","unstructured":"Gordon, J., Brown, M. & Reynolds, M. Cell-based methods for determination of efficacy for candidate therapeutics in the clinical management of cancer. Diseases 6, 85 (2018).","journal-title":"Diseases"},{"key":"60339_CR33","doi-asserted-by":"publisher","first-page":"27071","DOI":"10.1038\/srep27071","volume":"6","author":"R Wang","year":"2016","unstructured":"Wang, R. et al. Stellettin B induces G1 arrest, apoptosis and autophagy in human non-small cell lung cancer A549 cells via blocking PI3K\/Akt\/mTOR pathway. Sci. Rep. 6, 27071 (2016).","journal-title":"Sci. Rep."},{"key":"60339_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/mps1020019","volume":"1","author":"M Naik","year":"2018","unstructured":"Naik, M., Brahma, P. & Dixit, M. A cost-effective and efficient chick ex ovo CAM assay protocol to assess angiogenesis. Methods Protoc. 1, 19 (2018).","journal-title":"Methods Protoc."},{"key":"60339_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/ijms25020837","volume":"25","author":"C Mesas","year":"2024","unstructured":"Mesas, C. et al. Experimental tumor induction and evaluation of its treatment in the chicken embryo chorioallantoic membrane model: a systematic review. Int. J. Mol. Sci. 25, 837 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"60339_CR36","doi-asserted-by":"publisher","first-page":"e98921","DOI":"10.1172\/jci.insight.98921","volume":"3","author":"X Jiang","year":"2018","unstructured":"Jiang, X. et al. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. JCI Insight. 3, e98921 (2018).","journal-title":"JCI Insight"},{"key":"60339_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.toxrep.2019.10.004","volume":"6","author":"SK Hassan","year":"2019","unstructured":"Hassan, S. K. et al. Antitumor activity of Cuphea ignea extract against benzo(a)pyrene-induced lung tumorigenesis in Swiss Albino mice. Toxicol. Rep. 6, 1071\u20131085 (2019).","journal-title":"Toxicol. Rep."},{"key":"60339_CR38","doi-asserted-by":"publisher","first-page":"1106733","DOI":"10.3389\/fphar.2023.1106733","volume":"14","author":"H Alghetaa","year":"2023","unstructured":"Alghetaa, H. et al. Resveratrol attenuates staphylococcal enterotoxin B-activated immune cell metabolism via upregulation of miR-100 and suppression of mTOR signaling pathway. Front. Pharmacol. 14, 1106733 (2023).","journal-title":"Front. Pharmacol."},{"key":"60339_CR39","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2165\/11207770-000000000-00000","volume":"71","author":"KP Garnock-Jones","year":"2011","unstructured":"Garnock-Jones, K. P. Nilotinib. Drugs 71, 1579\u20131590 (2011).","journal-title":"Drugs"},{"key":"60339_CR40","doi-asserted-by":"crossref","unstructured":"Hunter, R. et al. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. CD000440 (2003).","DOI":"10.1002\/14651858.CD000440"},{"key":"60339_CR41","unstructured":"Sahi, N., Nguyen, R. & Patel, P. Loperamide. In StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557885\/ (StatPearls Publishing, 2025)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60339-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:10:23Z","timestamp":1786630223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60339-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60339"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60339-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25309"}}